Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12580731 | 0.89 | GLA (0.58) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL8485553 | 0.87 | LMNA (0.51) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL8485558 | 0.87 | LMNA (0.51) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL8972806 | 0.86 | GLA (0.55) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL5653522 | 0.86 | GLA (0.55) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL21852158 | 0.85 | ALDH1A1 (0.54) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL12947921 | 0.84 | TSHR (0.53) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL24590426 | 0.82 | FKBP1A (0.48) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL23771200 | 0.82 | FKBP1A (0.48) | TSHRLMNAGLAPOLBFKBP1A | |
| SCHEMBL4044701 | 0.82 | FKBP1A (0.48) | TSHRLMNAGLAPOLBFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-3870575-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210393633-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-12-23 | — | — | US | disclosed |
| WO-2021046437-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-09-23 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | TSHR 3766/4885LMNA 393/4885GLA 101/4885 |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | TSHR 3187/4885LMNA 378/4885GLA 4258/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | TSHR 4798/4885LMNA 3551/4885GLA 4827/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | TSHR 847/4885LMNA 4568/4885GLA 3833/4885 |
| US-20210393633-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | TSHR 4832/4885LMNA 3667/4885GLA 2574/4885 |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | TSHR 3807/4885LMNA 1539/4885GLA 3151/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | TSHR 1003/4885LMNA 48/4885GLA 1321/4885 |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | TSHR 4523/4885LMNA 2354/4885GLA 954/4885 |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | TSHR 396/4885LMNA 4598/4885GLA 3045/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | TSHR 3904/4885LMNA 2179/4885GLA 2759/4885 |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | TSHR 4809/4885LMNA 4431/4885GLA 4073/4885 |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | TSHR 3807/4885LMNA 1539/4885GLA 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.